UCL and Eisai have entered a drug discovery and development collaboration to investigate new ways of treating neurological diseases such as Alzheimer’s, Parkinson’s and other related disorders. The goal of the collaboration is to identify and validate novel drug targets, develop new therapeutics and evaluate them in proof-of-concept trials.    UCL and Eisai will form a Therapeutic Innovation Group (TIG) comprised of scientists from both companies to facilitate the discovery and asses...